Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation.

What Was Tested

This randomized controlled trial looks at Deamino Arginine Vasopressin.

This study was designed to evaluate prospectively the impact of on-site coagulation testing on blood product use, operative time, and intraoperative management of microvascular bleeding.

Why It Was Studied

Although laboratory coagulation tests permit a rational approach to both diagnosis and management of coagulation disorders after cardiopulmonary bypass, their clinical utility is limited by delays in obtaining results.

Patients who underwent cardiac procedures involving cardiopulmonary bypass and subsequently developed microvascular bleeding were randomly assigned to receive either standard therapy (n = 36) or therapy defined by a treatment algorithm based on results from an on-site coagulation monitoring laboratory (n = 30).

Who Took Part

PubMed tags the participants as both men and women.

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Deamino Arginine Vasopressin and who got the comparison, which limits bias.

What Was Measured

Although laboratory coagulation tests permit a rational approach to both diagnosis and management of coagulation disorders after cardiopulmonary bypass, their clinical utility is limited by delays in obtaining results.

The subject headings attached to it are Blood Coagulation Tests, Blood Transfusion, Cardiac Surgical Procedures, Clinical Protocols, Deamino Arginine Vasopressin, Hemorrhage and Hemostasis, Surgical.

What This Means in Plain Language

The paper is a randomized study of Deamino Arginine Vasopressin.

The publication is from 1994 (The Journal of thoracic and cardiovascular surgery), a journal based in United States.

More context: all human trials.